
Opinion|Videos|August 28, 2024
Optimizing ICI and TKI Combinations + Dose Reductions
Medical experts explore dose reduction strategies, alternative therapies, and clinical pearls for optimizing health outcomes in renal cell carcinoma patients treated with immune checkpoint inhibitor and tyrosine kinase inhibitor combinations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5







































